Stockscreener 앱 받기
10.57
2.92%
0.30
시간 외 거래:
10.59
0.02
+0.19%
전일 마감가:
$10.27
열려 있는:
$10.19
하루 거래량:
771.14K
Relative Volume:
0.68
시가총액:
$1.60B
수익:
$58.44M
순이익/손실:
$-80.74M
주가수익비율:
-8.8083
EPS:
-1.2
순현금흐름:
$-76.32M
1주 성능:
-6.46%
1개월 성능:
+7.42%
6개월 성능:
+71.31%
1년 성능:
+224.23%
1일 변동 폭
$10.07
$10.66
1주일 범위
$9.76
$11.48
52주 변동 폭
$1.995
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
15 CROSBY DRIVE, BEDFORD, MA
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Vanguard Group Inc's Strategic Reduction in Ocular Therapeutix I - GuruFocus.com
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix stock soars to 52-week high of $11.64 By Investing.com - Investing.com South Africa
Ocular Therapeutix (NASDAQ:OCUL) Reaches New 1-Year HighHere's What Happened - MarketBeat
Ocular Therapeutix stock soars to 52-week high of $11.64 - Investing.com India
Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Drops By 18.1% - MarketBeat
Assenagon Asset Management S.A. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, - openPR
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, Clinical Trials, Therapies, and Key Companies Involved by DelveInsight | Ocular Therapeutix, Aldeyra Therapeutics, Aciex Therapeutics - Barchart
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? - MSN
HC Wainwright Reaffirms “Buy” Rating for Ocular Therapeutix (NASDAQ:OCUL) - Defense World
SG Americas Securities LLC Purchases Shares of 45,187 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Sets New 52-Week HighTime to Buy? - MarketBeat
Ocular Therapeutix stock soars to 52-week high of $11.34 - Investing.com
Ocular Therapeutix stock soars to 52-week high of $11.34 By Investing.com - Investing.com UK
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load? - Simply Wall St
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 4.9%Here's Why - MarketBeat
Ocular Therapeutix shares hold as analyst reiterates Buy rating By Investing.com - Investing.com UK
Ocular Therapeutix Inc (OCUL) expanding its growth trajectory ahead - SETE News
Ocular Therapeutix (NASDAQ:OCUL) Coverage Initiated at Scotiabank - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Earns "Buy" Rating from HC Wainwright - MarketBeat
Ocular Therapeutix speeds up wet AMD trial enrollment - Investing.com
Taking a Closer Look At Ocular Therapeutix Inc (OCUL) Following Its Recent Trade - Knox Daily
Ocular Therapeutix speeds up wet AMD trial enrollment By Investing.com - Investing.com South Africa
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD - GlobeNewswire
Ocular Therapeutix Inc (OCUL) Stock: A Year of Market Fluctuations - The InvestChronicle
What is the investor’s view on Ocular Therapeutix Inc (OCUL)? - US Post News
Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors - Seeking Alpha
Ocular Therapeutix Inc [OCUL] stock for 16,525 USD was sold by Nayak Sanjay - Knox Daily
Amendment to 2019 Inducement Stock Incentive Plan Boosts Ocular Therapeutix’s Shares - MarketBeat
Ocular Therapeutix expands stock incentive plan - Investing.com India
Ocular Therapeutix expands stock incentive plan By Investing.com - Investing.com South Africa
Ocular Therapeutix Expands Stock Incentive Plan for Employees - TipRanks
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ocular Therapeutix : Amendment No. 4 to 2019 Inducement Stock Incentive Plan Form 8 K - Marketscreener.com
Market Momentum Report: Ocular Therapeutix Inc (OCUL)’s Negative Close at 9.32 - The Dwinnex
Ocular Therapeutix Inc (OCUL) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Ocular Therapeutix™ to Present at October Ophthalmology Meetings - The Manila Times
Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength - Yahoo Finance
What was Ocular Therapeutix Inc (OCUL)’s performance in the last session? - US Post News
Brokerages Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) PT at $15.67 - MarketBeat
Objective long/short (OCUL) Report - Stock Traders Daily
Marshall Wace LLP Purchases New Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Technical analysis of Ocular Therapeutix Inc (OCUL) stock chart patterns - US Post News
Potential Price Increase for Ocular Therapeutix Inc (OCUL) After Recent Insider Activity - Knox Daily
Daily Market Movement: Ocular Therapeutix Inc (OCUL) Sees a 0.23 Increase, Closing at 8.70 - The Dwinnex
Nantahala Capital Management LLC Buys Shares of 1,000,000 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Investors in cash trouble should check out Ocular Therapeutix Inc (OCUL) - SETE News
Ocular Therapeutix's SWOT analysis: stock poised for growth amid retina focus shift - Investing.com
Second Line Capital LLC Buys New Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):